Context Announces Presentation of New Preclinical Data on Apristor in Combination with a Cdk4/6 Inhibitor at San Antonio Breast Cancer Symposium

On November 13, 2018 Context Therapeutics, a clinical-stage biotechnology company, reported that new preclinical data on Apristor, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium taking place on December 4-8, 2018 in San Antonio, TX (Press release, Context Therapeutics, NOV 13, 2018, View Source [SID1234531332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the conference, Dr. Deepak Lala, Ph.D., Chief Technology Officer of Context Therapeutics will present preclinical data highlighting Apristor in inhibiting breast cancer cell proliferation alone or when combined with Palbociclib, a CDK4/6 inhibitor or FASLODEX (Fulvestrant), an estrogen receptor antagonist. The study was conducted in collaboration with Dr. Carol Lange, Ph.D., Tickle Family Chair of Breast Cancer Research at the University of Minnesota,

The poster details are as follows:

Poster Title: The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors in preclinical in-vitro breast cancer models

Poster: #926

Session Date: Saturday, 12/8/201

Session Time: 7:30 AM – 9:00 AM CT

Location: Henry B Gonzalez Convention Center/ Poster Hall 1

For more information on SABCS 2018, please visit View Source

About Apristor

Apristor (onapristone extended release) is Context’s wholly owned, first-in-class, orally active extended release formulation of onapristone, a full progesterone receptor antagonist. Progesterone receptor [PR] plays a critical role in driving breast cancer disease progression as well as therapeutic resistance to first line antiestrogen or Cdk4/6 inhibitor therapy. Apristor is the only full PR antagonist that is being developed to target breast cancer. Apristor has the potential to transform the treatment of breast cancer, through the potent inhibition of PR signaling thereby blocking breast cancer cell proliferation and overcoming resistance to first line antiestrogen and Cdk4/6 inhibitor therapy.